Zhejiang Huahai Pharmaceutical (SHA:600521) subsidiary Zhejiang Huahai Jiancheng Pharmaceutical passed the US Food and Drug Administration's current good manufacturing practice pre-approval inspection, according to a Wednesday filing with the Shanghai bourse.
The drug company's assessment covers its overall factory quality management system and the gabapentin active pharmaceutical ingredient, the filing said.
Gabapentin is used for epileptic and neuropathic pain treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments